If ACAD wants to buy NEU , the last thing they would do is announce a ph2 trial of 2591 in Retts or FXS. These trials cost about $20M each.
It’s hard to think of another reason they are so quiet about commencing work on them both.
Ann: DAYBUE (trofinetide) 2024 net sales US$348 million, page-29
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.90 |
Change
-0.060(0.46%) |
Mkt cap ! $1.602B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.02 | $12.70 | $949.4K | 73.91K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 564 | $12.89 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.91 | 1803 | 8 |
View Market Depth
| Last trade - 10.53am 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |